引言2024 年第 47 届圣安东尼奥乳腺癌研讨会（San Antonio Breast Cancer Symposium，SABCS）将于 2024 年 12 月 10-13 日在美国圣安东尼奥隆重召开。SABCS 是规模最大的聚焦于乳腺恶性肿瘤的全球盛会，届时，来自世界各地的行业领袖、专家共同探讨乳腺癌领域的最新研究进展。近期，官方已公布大会详细日程，有 20 ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

导读多发性硬化（MS）是一种免疫介导的中枢神经系统炎性脱髓鞘疾病。近年来，随着国内外指南共识的更新，以及多种疾病修饰治疗（DMT）药物的研发和应用，MS的标准化诊疗水平得以显著提升。然而，我国MS管理仍面临着诊断延迟、DMT药物治疗率和规范化随访率低 ...

NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia ...

PharmaJet Poster Presentation at Cancer Immunotherapy Conference Highlights How Needle-free Technology is Enhancing Oncology ...

Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial ...

This Yonhap file photo shows South Korean psychiatrist and family counseling specialist Dr. Oh Eun-young. (Yonhap) SEOUL, Oct ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 2024 GlobeNewswire October 23, 2024 SAN FRANCISCO and SINGAPORE ...

The 13th Shanghai International Magic Festival, an important program of the ongoing 23rd China Shanghai International Arts ...

Xenetic Biosciences, Inc. (NASDAQ:XBIO) (”Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology ...